List of Excipients in Branded Drug PIQRAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	CELLULOSE, MICROCRYSTALLINE	2027-01-18
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	FERRIC OXIDE RED	2027-01-18
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	FERROSOFERRIC OXIDE	2027-01-18
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	HYPROMELLOSE	2027-01-18
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	MAGNESIUM STEARATE	2027-01-18
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	MANNITOL	2027-01-18
Novartis Pharmaceuticals Corporation	PIQRAY	alpelisib	0078-0708	POLYETHYLENE GLYCOL 4000	2027-01-18

Piqray Excipient Strategy and Commercial Opportunities for Alpelisib

Last updated: August 13, 2026

Piqray (alpelisib) is an oral, film-coated immediate-release tablet marketed by Novartis for PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with fulvestrant. Its commercial excipient opportunity is concentrated in generic and lifecycle reformulation work, not in clinical differentiation of the active ingredient. The main formulation priorities are dose uniformity across 50 mg, 150 mg, and 200 mg tablets; physical stability; lactose and gastrointestinal tolerability; tablet manufacturability; and regulatory comparability.

The current formulation uses conventional direct-compression or dry-granulation excipients, including lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hypromellose, magnesium stearate, talc, titanium dioxide, polyethylene glycol, and iron oxide colorants, according to U.S. labeling. No extended-release, lipid-based, or drug-device delivery system is identified in the FDA-approved product label. [1]

What is Piqray and how is alpelisib formulated?

Piqray contains alpelisib, a selective phosphatidylinositol-3-kinase alpha inhibitor. The product is supplied as immediate-release tablets in three strengths:

Strength	Dosage form	Typical commercial role
50 mg	Film-coated tablet	Dose reduction and titration
150 mg	Film-coated tablet	Dose reduction or alternative dosing
200 mg	Film-coated tablet	Standard once-daily dose

The recommended dose is 300 mg once daily, usually administered as two 150 mg tablets or one 300 mg total daily dose assembled from available tablets, depending on the approved product presentation. Dose reductions commonly require 250 mg and 200 mg daily regimens, making lower-strength tablets commercially important for treatment continuity. [1]

What excipients are used in Piqray tablets?

The label identifies the following functional excipient categories:

Excipient	Primary formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet bulk	Potential tolerability and supplier qualification issue
Microcrystalline cellulose	Diluent, dry binder, compression aid	Supports hardness and compactability
Sodium starch glycolate	Superdisintegrant	Controls tablet breakup and dissolution
Hypromellose	Film former and coating polymer	Supports coating integrity and appearance
Magnesium stearate	Lubricant	Controls ejection and tooling performance
Talc	Coating aid and anti-tacking agent	Supports coating process control
Titanium dioxide	Opacifier and colorant	Subject to regional regulatory scrutiny
Polyethylene glycol	Plasticizer in the film coat	Improves coating flexibility
Iron oxides	Tablet-color differentiation	Helps prevent strength-selection errors

The exact quantitative composition, particle-size specifications, supplier grades, and process parameters are generally not disclosed in the public label. Those attributes are likely to be controlled through the marketing authorization holder's CMC specifications and manufacturing process.

What excipient strategy is most relevant for Piqray generics?

A generic alpelisib developer should prioritize Q1/Q2 similarity, dissolution robustness, and manufacturing reproducibility. The formulation is not technically complex, but alpelisib's low daily dose relative to tablet mass makes content uniformity and blend homogeneity important.

Which excipients are most difficult to substitute?

Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate are likely to be the highest-impact excipients because they directly affect:

• Blend flow and segregation
• Tablet tensile strength
• Disintegration time
• Dissolution profile
• Lubrication sensitivity
• Scale-up reproducibility

A formulation using the same excipient classes can still produce materially different dissolution results if it uses different grades, particle-size distributions, moisture levels, or surface areas. A generic developer should therefore treat excipient grade as a critical material attribute rather than a simple supplier-selection issue.

Is lactose substitution commercially attractive?

Lactose-free or low-lactose alpelisib could have a limited niche, but the commercial case is weaker than for pediatric, geriatric, or chronic gastrointestinal products. Piqray is an oncology medicine used in adults, and the label does not identify lactose intolerance as a central product limitation.

Potential substitutes include mannitol, anhydrous dibasic calcium phosphate, pregelatinized starch, and additional microcrystalline cellulose. Each substitution changes tablet density, compactability, moisture behavior, and dissolution. A lactose-free formulation would need a clear commercial rationale, such as:

• Differentiated positioning in markets with lactose excipient restrictions
• Improved stability under humid conditions
• Reduced tablet weight or increased mechanical strength
• Supply-chain resilience
• A formulation patent or product-specific regulatory advantage

Without a meaningful clinical or manufacturing benefit, lactose substitution may increase development and regulatory cost without expanding the addressable market.

What formulation improvements could create commercial opportunities?

The strongest opportunities are likely to come from manufacturing economics, patient-use simplification, and regional regulatory adaptation.

Smaller tablets and dose-flexible presentations

Patients may require dose reductions because of hyperglycemia, rash, diarrhea, colitis, pneumonitis, or other adverse reactions identified in the prescribing information. [1] A formulation strategy that provides reliable 50 mg, 150 mg, and 200 mg tablets with consistent appearance and rapid dissolution can reduce medication errors and support dose modification.

A commercially attractive generic portfolio would include:

Product concept	Potential value
50 mg tablet	Supports dose reduction and titration
150 mg tablet	Enables standard 300 mg daily dosing with two tablets
200 mg tablet	Supports reduced-dose regimens
Unit-dose blister	Improves adherence and shipment control
Moisture-protective bottle or blister	Supports stability in humid markets
Color-coded strengths	Reduces strength-selection errors

Improved moisture protection

Alpelisib tablets may be sensitive to moisture through effects on disintegration, coating, or chemical stability. A generic sponsor could evaluate high-barrier aluminum-aluminum blister packaging, desiccant bottles, or moisture-resistant polymer bottles.

The opportunity is strongest in markets with high humidity, weak pharmacy storage controls, or long distribution chains. Packaging changes can be commercially useful even where the tablet composition remains close to the reference product.

Reduced coating complexity

The reference product uses colored film coating. A generic manufacturer could reduce coating weight, optimize pigment loading, or use a simpler color system if the resulting product meets identification, stability, and bioequivalence requirements.

Color changes carry medication-error risk. Strength differentiation must remain clear, particularly because alpelisib dosing frequently changes during treatment.

Improved excipient supply resilience

Novartis and generic manufacturers face exposure to shortages or qualification failures involving common excipients. Dual sourcing can be developed for:

• Lactose monohydrate
• Microcrystalline cellulose
• Sodium starch glycolate
• Hypromellose
• Magnesium stearate
• Film-coating systems

The most valuable supplier relationships are likely to involve validated equivalent grades rather than new chemical excipients. A supplier with regulatory documentation, consistent particle-size control, and multi-region manufacturing can capture value through qualification support and continuity agreements.

What FDA regulatory requirements apply to Piqray excipients?

The FDA treats excipients as part of the finished dosage-form CMC package. An alpelisib generic submitted through an abbreviated new drug application would generally need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to the applicable FDA product-specific guidance and ANDA requirements. [2,3]

Relevant regulatory issues include:

1. Inactive ingredient acceptability under FDA regulations and the Inactive Ingredient Database.
2. Strength-specific composition and manufacturing controls.
3. Dissolution performance across relevant pH conditions.
4. Content uniformity and assay.
5. Stability under ICH conditions.
6. Container-closure performance.
7. Control of elemental impurities, residual solvents, nitrosamines, and microbial quality where applicable.
8. Demonstration that colorants and coating materials meet U.S. and target-market requirements.

A formulation using novel excipients would face a higher regulatory burden than one using established compendial materials. For this product, established excipients are likely to offer the best balance between development speed and differentiation.

What is the Orange Book status of Piqray?

Piqray is an FDA-approved prescription drug and is listed in the FDA's Orange Book under alpelisib tablets. The reference product is marketed by Novartis Pharmaceuticals Corporation. [4]

The regulatory exclusivity and patent analysis should distinguish among:

• New chemical entity exclusivity
• Use patents
• Composition-of-matter patents
• Formulation patents
• Manufacturing-process patents
• Pediatric exclusivity, if granted
• Patent-term extensions

Piqray received FDA approval in May 2019. Its five-year new chemical entity exclusivity period would ordinarily have prevented an ANDA with a Paragraph IV certification from being approved before May 2024, subject to the specific Orange Book listing and regulatory history. [1,4]

Patent expiration dates must be taken from the current Orange Book, USPTO records, and applicable patent-term-adjustment or patent-term-extension data. Public patent records associated with alpelisib may cover the compound, therapeutic use, salts, formulations, or manufacturing methods. The commercial launch date for a generic depends on the earliest enforceable patent barrier, litigation outcomes, settlement terms, and any 180-day exclusivity rights.

When does Piqray lose exclusivity and when could generics launch?

The principal regulatory exclusivity barrier began with the May 2019 FDA approval. The five-year NCE period therefore reached its ordinary endpoint in May 2024. That date did not automatically create an open market because listed patents and litigation can continue to restrict approval or launch. [1,4]

What Paragraph IV risks exist for alpelisib?

A Paragraph IV challenger could assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Filing an ANDA with Paragraph IV certification can trigger patent litigation under the Hatch-Waxman framework. A timely notice may also create a potential 180-day generic exclusivity period for the first qualifying applicant, depending on FDA determinations. [5]

The principal challenger strategies are likely to involve:

• Invalidity attacks based on obviousness or lack of written description
• Noninfringement arguments focused on excipient composition
• Carve-outs for patented methods of use
• Certification that a formulation patent does not cover the proposed product
• Challenges to patent-term calculations
• Settlement negotiations involving an authorized generic or agreed launch date

A generic company may avoid some method-of-use exposure through a section viii statement and appropriate labeling carve-out. That strategy is less useful against patents covering alpelisib itself or the tablet formulation.

What patents protect Piqray and its excipient formulation?

Alpelisib's patent estate is expected to contain multiple layers, but the most commercially important distinction is between active-ingredient protection and formulation protection.

Patent layer	Typical protected subject matter	Excipient impact
Compound patent	Alpelisib chemical structure	Usually blocks direct generic substitution until expiry
Salt or solid-form patent	Crystalline form, salt, polymorph	May constrain API sourcing
Method-of-use patent	Treatment of PIK3CA-mutated breast cancer	May be addressed through label strategy
Formulation patent	Tablet composition, stability, dissolution	Directly relevant to excipient selection
Manufacturing patent	Synthesis, purification, crystallization	May affect API supplier freedom to operate
Combination patent	Alpelisib with fulvestrant or other agents	Can affect commercial labeling

Public disclosure does not establish that every excipient used in Piqray is patent-protected. Conventional ingredients such as lactose, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate are widely used and generally offer limited standalone patent differentiation. The defensible IP value is more likely to reside in specific ratios, processing conditions, dissolution profiles, stability outcomes, or combinations with alpelisib.

How strong is the Piqray formulation patent estate?

The formulation estate is likely weaker than the compound estate if it relies primarily on conventional excipients. A formulation patent can still create a meaningful barrier when it claims a narrow combination that produces an unexpected stability or bioavailability result.

Patent strength should be assessed against five factors:

1. Whether the claims require a specific excipient ratio.
2. Whether the claims require a defined dissolution profile.
3. Whether the claimed formulation is necessary for alpelisib exposure.
4. Whether alternative excipient systems can achieve bioequivalence.
5. Whether the patent has survived prosecution, opposition, or litigation.

For generic developers, a formulation with the same excipient classes but different quantitative ratios may provide a plausible design-around. That approach still requires comparative dissolution, stability, and bioequivalence work.

Which companies are challenging Piqray and what is the competitive landscape?

No specific challenger should be treated as commercially active without confirmation in FDA ANDA records, federal court filings, or company disclosures. The likely competitive field includes:

• Large generic manufacturers with oncology portfolios
• Indian manufacturers pursuing U.S. and European filings
• Regional generic companies targeting Europe, Canada, and emerging markets
• Contract development and manufacturing organizations offering alpelisib tablet platforms
• Authorized-generic or license-based suppliers if Novartis elects to commercialize one

The highest-value competitive advantages are likely to be regulatory timing, API access, tablet yield, packaging cost, and freedom to operate. Excipient innovation alone is unlikely to create a durable premium unless it supports a differentiated product claim or removes a material manufacturing constraint.

What licensing and partnering opportunities exist for Piqray excipients?

Potential licensing opportunities exist in four areas:

Excipient technology licensing

Companies with proprietary co-processed excipients could offer improved flow, compactability, or disintegration. The value proposition would depend on reduced tablet weight, better content uniformity, lower compression force, or faster scale-up.

Coating and packaging systems

High-barrier blister systems and low-weight film coatings may create more immediate commercial value than novel tablet excipients. These technologies can support global distribution and may reduce stability failures.

Generic development partnerships

A regional pharmaceutical company may license an alpelisib formulation, while a CDMO supplies development, bioequivalence, and commercial manufacturing. The critical diligence items are patent clearance, API source qualification, FDA filing status, and supply rights by territory.

Authorized-generic arrangements

A Novartis-linked authorized generic could accelerate market access and reduce litigation risk. Such arrangements are commercially sensitive and should not be assumed unless disclosed in company filings or settlement documents.

What geographic opportunities exist for alpelisib formulation suppliers?

The United States offers the largest value opportunity but has the highest patent and ANDA litigation exposure. Europe may provide earlier opportunities in countries where national patent positions, reimbursement, and tender structures differ. Emerging markets may place greater value on:

• Stable formulations without refrigeration
• Moisture-resistant packaging
• Lower-cost excipient systems
• Local manufacturing
• Flexible tablet presentations
• Reliable supply of common excipients

Titanium dioxide and certain colorants may require region-specific review. A global formulation should preserve core tablet performance while allowing local coating and packaging adaptations.

Key Takeaways

• Piqray is an immediate-release alpelisib tablet marketed in 50 mg, 150 mg, and 200 mg strengths.
• The formulation uses established excipients, including lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hypromellose, magnesium stearate, and conventional film-coating materials.
• The strongest excipient opportunities are in dose flexibility, moisture protection, supply resilience, and manufacturing efficiency.
• Lactose-free reformulation is technically feasible but has limited commercial value without a clear tolerability or market-access benefit.
• Piqray's five-year NCE exclusivity period ordinarily ended in May 2024, but patents and litigation may continue to control generic approval or launch.
• Formulation patents may be designed around if generic developers reproduce performance without copying protected ratios, processes, or dissolution parameters.
• The most valuable commercial assets are likely to be API access, regulatory timing, patent clearance, and reliable global manufacturing rather than novel excipients alone.

FAQs

Can Piqray tablets be manufactured without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, starch-based binders, or other established diluents. The replacement must preserve content uniformity, mechanical strength, disintegration, dissolution, and stability.

Does Piqray require a specialized drug-delivery system?

No specialized delivery system is identified in the FDA label. Piqray is supplied as an oral film-coated immediate-release tablet.

Can a generic alpelisib use different excipients from Piqray?

Yes. A generic may use different inactive ingredients if the formulation meets applicable FDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, quality, and stability.

Which Piqray strength is most commercially important?

The 150 mg strength is central to the standard 300 mg daily regimen, while the 50 mg and 200 mg strengths support dose reductions. A complete portfolio is more commercially useful than a single-strength launch.

Are Piqray excipients likely to create a standalone patent barrier?

Usually not. Conventional excipients have limited standalone exclusivity value. The greater risk comes from patents claiming specific excipient ratios, processing conditions, stability properties, or dissolution performance.

References

1. U.S. Food and Drug Administration. (2024). Piqray (alpelisib) prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

3. U.S. Food and Drug Administration. (2024). Alpelisib tablets: Product-specific guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. 44th ed. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.